Clinical Trial Update: A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 study comparing a treatment simplification with darunavir/ritonavir (800/100 mg) to a triple-drug regimen containing DRV/r in HIV-1 infected patients,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Janssen-Cilag S.p.A. | Conditions: Human Immunodeficiency Virus 1 | Phase 2 | Status: COMPLETED | Results posted: 2013-06-27